Absence of clinical relationship between oxidized low density lipoproteins and diabetic peripheral neuropathy: a case control study by Alma Rosales-Hernandez et al.
Rosales-Hernandez et al. Lipids in Health and Disease 2014, 13:32
http://www.lipidworld.com/content/13/1/32RESEARCH Open AccessAbsence of clinical relationship between oxidized
low density lipoproteins and diabetic peripheral
neuropathy: a case control study
Alma Rosales-Hernandez1, Audrey Cheung1, Peter Podgorny1, Cynthia Chan1 and Cory Toth1,2*Abstract
Background: The pathophysiology of diabetic peripheral neuropathy (DPN) is complex and uncertain. A potential
comorbidity in diabetes mellitus (DM) that may contribute to greater severity of DPN is a lipid disorder, such as
with elevated cholesterol, low density lipoproteins or triglycerides. Oxidized low density lipoprotein (oxLDL) is a
form of cholesterol that exerts direct toxic effects and contributes to pathogenicity through ligating a receptor
called lectin-like receptor (LOX-1).
Methods: We examined plasma oxLDL levels in cohorts of patients with DPN with neuropathic pain (NeP), DPN
patients without NeP, DM patients without DPN, patients with idiopathic peripheral neuropathy, and control
subjects without DM or neuropathy. Our outcome measure was extent of oxLDL elevation, measured as fasting
with Enzyme-Linked ImmunoSorbant Assay (ELISA) studies. Severity of diabetes was assessed using hemoglobin
A1C measurements. Neuropathic severity was measured with the Utah Early Neuropathy Score (UENS). We
hypothesized that DPN presence would be associated with oxLDL elevations.
Results: A total of 115 subjects (47 with DPN and NeP, 23 with DPN without NeP, 12 with diabetes only, 13 with
idiopathic peripheral neuropathy, and 20 control subjects without diabetes or neuropathy) were studied. Duration
of diabetes and diabetic glycemic measures were similar between populations with DM. Severity of DPN was similar
between cohorts with DPN and NeP and DPN without NeP. Plasma oxLDL levels were similar between all cohorts,
without any elevation in the presence of DM noted in any cohort with DM.
Conclusions: oxLDL levels are not different in patients with DPN, and their lack of greater presence suggests that
any pathogenic role in human DPN is likely limited.
Keywords: Type 2 diabetes mellitus, Cholesterol, Oxidized low density lipoprotein, Diabetic neuropathy, Diabetic
neuropathic painIntroduction
Diabetic polyneuropathy (DPN) is a common and disab-
ling complication of human diabetes mellitus (DM) seen
in up to 50% of patients, leading to sensory, motor and/
or autonomic dysfunction [1]. There are several potential
mechanisms postulated to contribute to development of
DPN, including: 1) excessive sorbitol-aldose reductase path-
way flux; 2) protein kinase C (PKC) isoform(s) overactivity;* Correspondence: corytoth@shaw.ca
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article, unless otherwise stated.3) increased oxidative and nitrative stress; 4) microangiop-
athy; 5) accumulation of advanced glycation end products
(AGEs) and interaction with their receptor (RAGE); and
6) failure of neurotrophic support. However, studies to
date have failed to show therapeutic benefit when many of
these pathways have been targeted clinically.
A common association with DM is the presence of a
lipid disorder, or hyperlipidemia. This may include hyper-
triglyceridemia, elevated cholesterol, or may occur as part
of a metabolic syndrome. Although this is clearly a risk
factor for cerebrovascular and cardiovascular disease,
hyperlipidemia may also influence the peripheral nervous
system, possibly correlating with progression of DPN [2]ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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neuropathy [3]. Complicating matters further is the possi-
bility that statin medications used for treatment of hyper-
lipidemia may also contribute to peripheral neuropathy
[4-6]. However, it remains unclear if either hyperlipidemia
or its treatment has a true relationship with initiation or
progression of peripheral neuropathic conditions.
An important form of cholesterol is called oxidized
low density lipoprotein (oxLDL), which is known to have
a critical function in the development of atherosclerosis.
Along with its receptor, the lectin-like oxLDL receptor
(LOX)-1 [7,8], both oxLDL and LOX-1 contribute to
intracellular oxidative stress and inflammation injury
within vascular tissues as well as in the immune system
[9,10]. This may exist in an additive state with DM, as
both oxLDLs and hyperglycemia increase LOX-1 expres-
sion [11,12]. In murine models, high fat ingestion leads
to significantly increased plasma oxLDL levels in com-
bination with morphological and functional evidence of
peripheral neuropathy before hyperglycemia develops
[13]. Also, oxLDLs contribute to oxidative stress and in-
jury in dorsal root ganglia sensory neurons in vitro via a
LOX-1 mechanism related to activation of nicotinamide
adenine dinucleotide phosphate oxidase [13]. These data
not only suggest that oxLDL and LOX-1 may contribute
to DPN, but that they may also lead to development of
peripheral neuropathy even in the absence of DM. This
preclinical finding has not yet been confirmed in human
studies.
We hypothesized that patients with DM and DPN
would have higher levels of plasma oxLDL than patients
with DM without DPN and as compared to control sub-
jects. Furthermore, we postulated that patients with
DPN subjected to neuropathic pain (NeP) would have
greater oxLDL levels than those without NeP, based
upon preclinical studies suggesting that curcumin, a
molecule whose activity includes LOX-1 antagonism
[14-16], relieves neuropathic pain including that associ-
ated with DPN [17-19]. As such, we performed a multi-
cohort study to measure plasma oxLDL levels in adult
patients with type 2 DM and control subjects for oxLDL
levels to determine association with presence and sever-
ity of DPN. In addition, we recruited subjects with idio-
pathic peripheral neuropathy for comparison to the
subjects with DPN. Should oxLDL be determined to be
a risk factor for presence and greater severity of DPN,
potential therapeutic pathways could be examined in the
future.
Results
Patient and control subjects
A total of 128 potential subjects were screened for study
involvement. Of these, 13 were excluded due to inability
to perform phlebotomy (3 subjects), unclear presence ofperipheral neuropathy (5 subjects), presence of possible
peripheral neuropathy in control subjects (2 subjects),
uncertain presence of NeP (1 subject with DPN), and in-
ability to perform arranged blood work testing (2 sub-
jects). Thus, a total of 115 subjects participated, including
20 healthy control subjects (16 women), 13 subjects with
idiopathic peripheral neuropathy (7 women), 12 subjects
with non-complicated DM (DM only) (6 women), 23 sub
diagnosed with DM with DPN without pain (DPN-NoP)
(7 women), and 47 subjects diagnosed with DM with DPN
with persistent pain (DPN-P) (17 women) (Table 1). Of
the assessed subjects with DPN, no other causation for
peripheral neuropathy was present. Subjects with idio-
pathic peripheral neuropathy had no identifiable cause
after detailed testing.
There was a significant difference in gender represen-
tation between control subjects and DM subjects (χ2 =
12.24, p < 0.001), but other comparisons had similar gender
representations for analysis (χ2 = 0.22-1.09, p = 0.30-63).
There were no significant differences in age representation
between groups for comparison (ANOVA, p = 0.45). For
DM subgroups, there were no significant differences in
durations of DM (ANOVA, F = 0.45-0.87, p = 0.35-57) or
with the presence of other diabetic complications (χ2 =
0.12-0.76, p = 0.44-0.72). There were no differences in
statin use between DPN subjects and DM only subjects
(χ2 = 0.12, p = 0.72), or for DPN-P subjects as compared to
DPN-NoP subjects (χ2 = 0.88, p = 0.35). However, statin use
was much more prevalent in DPN subjects as compared to
idiopathic neuropathy subjects (χ2 = 6.18, p = 0.01), and in
DM subjects versus control subjects (χ2 = 7.31, p = 0.01).
Primary outcome measure–oxidized low density
lipoprotein levels
No significant difference in oxLDL levels could be de-
tected between all subjects with DPN versus subjects with
DM only (ANOVA, 1633 ± 121 pg/ml vs. 1829 ± 721 pg/
ml, F = 0.22, p = 0.64) (Figure 1). DPN-P subjects had
similar levels of plasma oxLDL as DPN-NoP subjects
(ANOVA, 1703 ± 160 pg/ml vs. 1541 ± 195 pg/ml, F =
0.45, p = 0.51). With comparison of all subjects with DPN
and subjects with idiopathic peripheral neuropathy, levels
of oxLDL were again similar between groups (ANOVA,
1633 ± 121 pg/ml vs. 2149 ± 525 pg/ml, F = 2.73, p = 0.11).
In fact, those subjects with idiopathic peripheral neur-
opathy had a non-significant higher level of oxLDL despite
the absence of DM. Finally, there was no significant differ-
ence in oxLDL levels between all subjects with DM as
compared with control subjects (ANOVA, 1675 ± 170
pg/ml vs. 1913 ± 232 pg/ml, F = 0.64, p = 0.42).
Secondary outcome measures
For DM subgroups, there were no significant differences
in HbA1C levels between all DPN and DM only groups,



















(DPN-P) (n = 47)
Age 58.5 ± 12.7 years 60.7 ± 15.2 years 53.6 ± 14.4 years 61.1 ± 10.0 years 59.8 ± 10.3 years
Gender (males) 4/20 (20%) 6/13 (46%) 6/12 (50%) 16/23 (69%) 30/47 (64%)
Duration of Diabetes Mellitus 7.2 ± 4.6 years 8.6 ± 3.6 years 9.1 ± 3.3 years
Duration of Neuropathic Symptoms 6.8 ± 4.2 years 7.1 ± 4.7 years
Concomitant Diabetic Complications Present
(other than neuropathy) Concomitant
Vascular Risk Factors:
1/12 (8%) 6/23 (26%) 10/47 (21%)
Hypertension 3/20 (15%) 3/13 (23%) 8/12 (67%) 17/23 (74%) 21/47 (45%)
Hyperlipidemia 4/20 (20%) 2/13 (15%) 8/12 (67%) 15/23 (65%) 26/47 (55%)
Family History of Peripheral Neuropathy 0/20 (0%) 0/13 (0%) 0/12 (0%) 0/23 (0%) 0/47 (0%)
Concomitant Statin Use 4/20 (20%) 2/13 (15%) 7/12 (58%)* 14/23 (61%)* 23/47 (49%)*
Hemoglobin A1C (%) (4.3-6.1%) 5.2 ± 0.5 5.3 ± 0.8 7.4 ± 0.9* 7.4 ± 1.3* 7.8 ± 1.8*
Total Cholesterol (4.2-5.2 mmol/L) 4.5 ± 0.7 4.8 ± 0.8 3.8 ± 0.7 4.1 ± 1.0 4.2 ± 1.1
Triglycerides (0.6-2.3 mmol/L) 1.2 ± 0.4 1.4 ± 1.4 1.3 ± 0.7 1.6 ± 0.8 2.0 ± 1.1*
High Density Lipoprotein (>0.9 mmol/L) 1.5 ± 0.5 1.5 ± 0.5 1.3 ± 0.4 1.2 ± 0.3 1.3 ± 0.7
Low Density Lipoprotein (2.2-3.4 mmol/L) 2.9 ± 0.7 3.1 ± 1.1 2.2 ± 0.7 2.3 ± 0.9 2.3 ± 1.4
Toronto Clinical Neuropathy Score 0.5 ± 1.1 8.3 ± 3.6 0.6 ± 1.1 10.8 ± 4.0 14.5 ± 5.3ψ
Utah Early Neuropathy Score 0.6 ± 1.9 7.9 ± 3.9 0.5 ± 1.0 10.4 ± 4.7 14.3 ± 7.8ψ
Values shown are means ± standard deviations. *indicates p < 0.05 (one way ANOVA testing) for comparison of cohorts as compared to the control cohort. ψindicates

























Figure 1 Mean plasma oxLDL levels are demonstrated for each
group. There were no significant differences detected between any
groups for any of the relevant comparisons. Error bars denote
standard error of the mean (SEM).
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(ANOVA, F = 0.75-0.96, p = 0.33-68). HbA1C levels were
significantly different between the entire DM group and
control subjects (ANOVA, F = 38.8, p < 0.0001), as well as
for DPN subjects when compared to idiopathic peripheral
neuropathy subgroup (ANOVA, F = 21.9, p < 0.0001).
For all relevant comparisons, there were no statistically
significant differences in total cholesterol (multiple
ANOVAs, F = 0.04-3.74, p = 0.06-0.85) or HDL (multiple
ANOVAs, F = 0.01-2.01, p = 0.16-0.91) between subgroups.
Triglycerides were higher in all subjects with DM as com-
pared to control subjects (ANOVA, F = 4.9, p < 0.05), but
other relevant comparisons showed similar levels of
triglycerides between groups (multiple ANOVAs, F = 1.49-
3.38, p = 0.06-0.23). Also, and interestingly, low density
lipoprotein (LDL) levels were lower in DM subjects as
compared to control subjects (ANOVA, F = 4.4, p = 0.04)
and were also lower in all DPN subjects as compared
to idiopathic neuropathy subjects (ANOVA, F = 4.2,
p = 0.04); there were no differences in LDL levels between
DPN subjects as compared to DM only subjects (ANOVA,
F = 0.1, p = 0.74) or for DPN-NoP subjects as compared to
DPN-P subjects (ANOVA, F = 0.0, p = 0.98).
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of interest
Potential relationships were sought for oxLDL levels
(independent variable) and TCSS, UENS, total cholesterol,
and low density lipoprotein levels (dependent variables)
(Figure 2). For all subjects with DPN, there was no relation-
ship between oxLDL levels and either of TCSS (R2 < 0.03,
p =NS) or UENS (R2 < 0.01, p =NS). For all DM subjects,
there was no relationship between oxLDL with either total
cholesterol (R2 < 0.02, p =NS) or low density lipoprotein
(R2 < 0.002, p =NS). Finally, two post-hoc tests were
performed. First, to examine the impact of statin medica-
tion use, the oxLDL levels of DM subjects taking statin
medications were compared to those of DM subjects not
taking statin medications; there was no significant differ-
ence between these subgroups (ANOVA, F = 1.20,
p = 0.28). Second, linear regression was performed to
compare total cholesterol and low density lipoprotein
levels–there was a significant relationship for measures
obtained in all subjects (R2 = 0.37, F = 42.7, p < 0.01).
Association with clinical severity of neuropathy and
diabetic complications
With clinical severity of peripheral neuropathy as the
dependent variable, there was no relationship between
UENS severity and oxLDL levels (R2 < 0.01, p = NS),
HbA1C (R2 = 0.05, p = 0.20), total cholesterol (R2 = 0.01,
p = NS), triglyceride levels (R2 < 0.01, p = NS), and LDL
levels (R2 = 0.02, p = NS). Likewise, there were no signifi-
cant relationships between TCSS severity and oxLDL
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Figure 2 Linear relationships were sought between oxLDL and clinica
measurements for lipids. For all subjects with DPN, there was no significa
TCSS (B). For all subjects with DM, there was no significant association betw
lipoprotein levels (D). Linear regression was performed, with R2 values prestotal cholesterol (R2 = 0.03, p =NS), triglycerides (R2 < 0.01,
p =NS), and LDL levels (R2 = 0.03, p =NS). Finally, there
was no association between the number of recorded dia-
betic complications and oxLDL levels (R2 = 0.01, p =NS).
Conclusions
We sought to determine if oxLDL levels were height-
ened in patients with DM-mediated DPN and related to
the presence of neuropathic pain in DPN-P patients.
Our results indicate that we were unable to determine
any relationship between plasma oxLDL levels and the
presence of DPN or the severity of DPN. There was also
no significant increase in plasma oxLDL levels in the
presence of DM as compared to a non-diabetic control
state. Furthermore, there was no detected worsening in
clinical severity of neuropathy with higher levels of
oxLDL, HbA1C, total cholesterol, triglycerides, or LDL
levels. Recently reported studies have also demonstrated
a lack of elevated oxLDL levels in patients with DPN or
DM without DPN when compared to control subjects
[20]. Although prior studies indicate a positive relation-
ship between any diabetic microvascular complication
and abnormalities in LDL, triglycerides, and non-HDL
cholesterol [21] with similar overall cholesterol results, it
remains unclear regarding any association between lipid
status and presence of peripheral neuropathy. Thus,
although preclinical studies have identified potential
mechanisms by which oxLDL may contribute to neuro-
degeneration, particularly in the presence of hypergly-

















 0             5            10            15            20           25
R  < 0.032
R  < 0.01
2


















 0           1           2            3            4           5            6
l scores of peripheral neuropathy as well as for laboratory
nt relationship between plasma oxLDL levels and the UENS (A) or
een plasma oxLDL levels and total cholesterol (C) or low density
ented for each association sought.
Rosales-Hernandez et al. Lipids in Health and Disease 2014, 13:32 Page 5 of 9
http://www.lipidworld.com/content/13/1/32The present findings should not be seen to discourage
against further investigations of other methods by which
hyperlipidemia could contribute to neurodegeneration in
DM patient populations. There is clinical evidence that
triglyceridemia contributes to progression of already
existing DPN [2], while each of total cholesterol, low-
density lipoprotein and triglyceride levels have been
positively associated with increasing cumulative inci-
dences [22] or greater severity [23] of diabetic peripheral
neuropathy. Furthermore, a low high density lipoprotein
level may also relate to presence of DPN [24]. The
mechanisms by which these forms of cholesterol may
impact upon peripheral nerve function and structure are
unclear. It is also difficult to simulate these human rela-
tionships in animal models; for example, mice have quite
low levels of low density lipoproteins, while most choles-
terol is transported by high density lipoproteins [25],
distinct from the human situation. Despite this issue,
wildtype mice fed high fat diets develop elevated plasma
oxLDL levels [13]. Peripheral nerve studies in transgenic
mice featuring highly increased plasma cholesterol are
untenable due to excessive short term mortality [25]. In
wildtype mice, a high fat diet plays an important role in
the severity of experimental DM [26,27], and it is even
possible that a high fat diet may lead to peripheral neur-
opathy in the absence of DM [28]. Thus, there is suffi-
cient preclinical and clinical data to suggest that an
association exists between lipid disorders and peripheral
neuropathy, but the potential mechanism has remained
elusive.
Further complicating our ability to understand rela-
tionships between lipid disorders and peripheral neur-
opathy is the controversial relationship of frequently
prescribed statin medications used for lipid disorder
management. Statins lower cholesterol through inhib-
ition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase. Statin use is extremely common [29,30],
particularly in diabetic subjects; in our study, over 50%
of DM subjects were taking statins. There are a number
of case series and case-control studies [6,31-33] along
with a recent cross-sectional study [30] suggesting a
relationship between statin use and peripheral neur-
opathy presence. However, there are also some contrast-
ing reports, suggesting that statins may have a beneficial
effect upon peripheral neuropathy in humans (limited to
hypotheses) [34,35] and rodents [36-38]. Nevertheless,
given the absence of a plausible mechanism by which
statins could induce peripheral neuropathy, the effect of
statins upon peripheral nerves remains unclear. In our
study, the use of statins was significantly more common
in the diabetic cohorts, which likely contributed to
relatively depressed LDL levels relative to Control
Subjects and Idiopathic Neuropathy Subjects. This is a
confounder that certainly impacts upon our results asstatins certainly will decrease oxLDL levels [39,40] in
our diabetic cohorts. This obstacle is difficult to over-
come in clinical studies, as the great majority of diabetic
patients now receive statin therapies. The washout of
statin medications would likely be required in future
studies of experienced DM patients to determine natural
oxLDL levels; alternatively, investigation of newly diag-
nosed DM patients prior to interventions may assist in
future determinations.
We chose to examine oxLDL due to its potential for
neurotoxicity. Known to have a critical function in the
development of atherosclerosis [7,41,42] along with its
receptor, the lectin-like oxLDL receptor (LOX)-1 [8], its
impact upon non-neural tissues has great substantiation.
The receptor LOX-1 has non-constitutive but dynamic-
ally inducible expression [43] driven by both oxLDLs
and hyperglycemia [11,44]. Along with oxLDL, LOX-1
contributes to intracellular oxidative stress and inflam-
mation injury [9,10]. In vitro, oxLDLs contribute to
oxidative stress and injury in DRG neurons via a LOX-1-
mediated mechanism related to activation of NAD(P)H
oxidase [13]. These data not only suggest that oxLDL/
LOX-1 may contribute to DPN, but that they may also
lead to development of peripheral neuropathy even in
the absence of DM. Dietary alterations may also play
roles: high-fat feeding in murine models significantly
increases plasma oxLDL as well as contributing to mor-
phological and functional evidence of peripheral neur-
opathy prior to development of hyperglycemia [13].
Therefore, although our study failed to identify higher
levels of oxLDL in human subjects with DPN (or even
only with DM), there is evidence to suggest that elevated
oxLDL levels can be neurotoxic.
Our findings are presented with limitations to be con-
sidered. Although we used a standard ELISA method to
measure oxLDL levels, there are different methods that
may be favored in some circumstancses [45]. Also, other
methods of analyses including in vivo measurement [46]
and ex vivo oxidation assays [47] exist. In some cases,
serum oxLDL levels [48,49] are measured instead of
plasma oxLDL levels [42,50]–it remains unclear which
technique may be most accurate. Studied subjects were
volunteers and were not randomly selected from a popu-
lation with type 2 DM with or without DPN and with or
without accompanying NeP. Our sample size was not
based upon a pre-determined power analysis. Patients
with type 1 DM were excluded due to potential differ-
ences in the pathophysiology of neurodegeneration and
to maintain a more homogeneic patient population. As
stated, gender matching between groups was not com-
plete as female subjects were overrepresented in the
control group. Also, statin use was much more common
in DM patients, although its use was not associated with
significant changes in measured oxLDL levels. The use
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chronic pain related to DPN may have impacted upon
oxLDL measurements in uncertain ways. Although total
cholesterol and low density lipoprotein levels were posi-
tively associated, there was no association found be-
tween lipid measurements and plasma oxLDL levels.
Clinical severity of neuropathy failed to correlate with
types of lipids measured or with HbA1C levels. Although
higher HbA1C levels are associated with risk of subclin-
ical neuropathy [51] and electrophysiological parameters
[52], HbA1C is not necessarily an independent predictor
of diabetic neuropathy although it is clearly associated
with other microvascular complications [53,54]. How-
ever, in prior studies examining DPN populations, the
clinical severity of DPN based upon the UENS was posi-
tively associated with age, duration of diabetes, height,
weight and HbA1C [55]. Our study population was
small, but the lipid status and HbA1C values are similar
to similar populations of DPN patients studied [55]. We
did not perform measurement of other markers for oxi-
dative stress such as glutathione, malondialdehyde, or
homocysteine, which may be elevated in DPN patients
[56] and could have provided comparison to measured
oxLDL and HbA1C levels. Finally, the individual group
sizes were small after categorization, and we cannot rule
out the possibility of type II errors contributing to the
lack of statistical associations determined–future larger
studies may be more forthright. However, there was a
distinct lack of relationship between oxLDL levels and
DPN manifestations found amongst studies performed
to date.
Our results demonstrated no visible associations be-
tween oxLDL levels in DM subjects and the presence or
severity of DPN. The results of our study do not exclude
the possibility of elevated levels of oxLDL at the level of
the peripheral nerve itself contributing to DPN [13,57];
we did also not study the role of the LOX-1 receptor in
our population. As a result, further more invasive studies
may determine other potential findings related to oxLDL.
Future studies may examine other aspects of lipid disor-
ders for relationship with complications of DM, including
DPN. Although our hypothesis of plasma oxLDL mediat-
ing greater presence and severity of DPN in subjects with
DM was not verified, it is possible that our results may be
confounded by some of the factors discussed above. Fac-
tors other than plasma oxLDL levels should be sought to




Ethical approval for this study was received from the
University of Calgary Centre for Advancement of Health.
Recruitment of subjects occurred from March 2010 untilJanuary 2013 using poster recruitment within the Neuro-
muscular, Neuropathic Pain and Endocrinology Clinics at
the University of Calgary. All subjects provided informed
written consent prior to their involvement.
Subjects with a diagnosis of pre-existing type 2 DM
were included following confirmation of diagnosis based
on Canadian Diabetes Association guidelines [58]. Briefly,
this required verification of two prior separate positive la-
boratory results from any of the following: fasting glucose
results of ≥ 7.1 mmol/L (126 mg/dL) or two oral glucose
tolerance tests leading to a 2 hour serum glucose of ≥
11.1 mmol/L (200 mg/dL), or a random glucose of ≥
11.1 mmol/L (200 mg/dL) at any time. The age of diagno-
sis of DM and the duration of symptoms of DPN (if
present) were recorded. During patient history, subjects
found to have DPN were also assessed for the presence of
other systemic illnesses, prior or current alcohol depend-
ence (based upon Diagnostic and Statistical Manual of
Mental Disorders (DSM)-IV criteria), toxin and medica-
tion exposures, and family history of neuropathy was doc-
umented to assess and exclude other potential causes of
peripheral neuropathy. The intake of anti-DM pharmaco-
therapies, statins used for management of hyperlipidemia,
and other medications (including those used for chronic
pain management) were recorded. The presence of dia-
betic complications other than that of DPN and other vas-
cular risk factors were also noted.
Subjects with a diagnosis of idiopathic peripheral neur-
opathy were included based upon negative laboratory
testing for other potential causes of peripheral neur-
opathy, including but not limited to laboratory testing as
previously described [59]. Control subjects were age-
matched and culled from non-diabetic friends and rela-
tives of patient subjects, as well as from staff working at
each of the clinics participating in this study.
Phlebotomy and oxidized low density lipoprotein testing
All subjects, fasting for a minimum of 12 hours, underwent
phlebotomy. This whole blood sample, stored in a plasma
tube with lithium heparin and gel (plastic tube, light green
top, Vacutainer, Becton Dickenson), was inverted gently
over the following 30 minutes. Then, the whole blood sam-
ple was placed on ice for another 30 minutes until it was
submitted to refrigerated centrifugation within a 1 hour
time period after phlebotomy, performed at 1500 g for
10 minutes. The supernatant was collected as plasma–this
liquid component was transferred to a 1.5 ml Eppendorf
tube while at 4°C. Following this, plasma was stored at
−80°C for 1-3 months until further testing was performed.
Plasma oxLDL was measured by Enzyme-Linked Immuno-
Sorbant Assay (ELISA) (Uscn Life Science Inc., Wuhan,
China) following their provided specifications.
Plasma samples were diluted 1000X using phosphate
buffered saline and standards were prepared according
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diluted samples were added to wells pre-coated with a
monoclonal antibody specific for oxLDL, with incuba-
tion occurring for 2 hours at 37°C. Following this, a
biotin-conjugated polyclonal antibody specific for the
oxLDL antibody was added. After successive washings,
an avidin conjugated to horseradish peroxidase was
added to each well and incubation followed again. Then,
a 3,3′,5,5′-Tetramethylbenzidine substrate solution was
added, providing a colorimetric change after interaction
with oxLDL. The enzymatic substrate reaction was termi-
nated with the addition of sulphuric acid. Colorimetric
change was measured immediately using a spectropho-
tometer with detection at 450 nm. The concentration of
human OxLDL in plasma was determined by comparing
the optical density of the samples to the standard curve
obtained by similar measurement of the standards.
Within one month of assessment, additional fasting
blood was evaluated for HbA1C, total cholesterol, tri-
glycerides, high density lipoprotein (HDL), and low
density lipoprotein (LDL) (Calgary Laboratory Services,
Calgary, AB, Canada) for all subjects.
Patients were excluded if potential causes for periph-
eral neuropathy other than DM were identified, if they
had impaired glucose tolerance only, or if they had a ju-
venile onset of DM or frank requirement for insulin at
diagnosis (i.e. possible type 1 DM). Lastly, subjects were
excluded if they refused concurrent laboratory testing.
Subject assessment and allocation
Each subject underwent a neurological examination that
permitted scoring for presence and severity of peripheral
neuropathy using the Toronto Clinical Scoring System
(TCSS) [60] and the Utah Early Neuropathy Scale
(UENS) [61]. This was performed by an unblinded Neur-
ologist subspecializing in Neuromuscular Diseases. After
clinical scales were completed, subjects were categorized
to have either no peripheral neuropathy (control subject
or DM only subject, both TCSS ≤ 3 and UENS ≤ 3) or to
have peripheral neuropathy (Idiopathic Neuropathy Sub-
ject or DPN subject both TCSS > 5 UENS > 6). Those
subjects with a TCSS score of 4-5 and/or a UENS score
of 4-6 were excluded due to uncertainty regarding the
presence or absence of peripheral neuropathy. As well,
control subjects were excluded from participation if
TCSS > 4 and/or UENS > 3. We further categorized sub-
jects with DPN as having NeP using the question “Do
you have pain on a daily or near daily basis?”. If subjects
answered “yes”, then they were asked to complete the
Douleur Neuropathique 4 questionnaire (DN4Q), which
categorizes pain as neuropathic or non-neuropathic in
nature with good sensitivity (82.9%) and specificity
(89.9%) [62]. Subjects scoring ≥4 on the DN4Q were cat-
egorized to have DPN with NeP (DPN-P), while subjectsdenying any pain or discomfort (answering “no”) were cat-
egorized as DPN without NeP (DPN-NoP). If subjects ad-
mitted to having pain, but had a score of <4 on the DN4Q,
they were excluded from further participation due to un-
certainty regarding the nature of experienced pain. In
order for subjects to be categorized as DPN-P, their pain
must be chronic, having persisted for ≥3 months with pain
severity estimated to be ≥40 mm on the 100 mm visual
analog scale (VAS) of the Short-Form-McGill Pain Ques-
tionnaire; otherwise, these subjects were excluded due to
uncertainty of classification as DPN-P or DPN-NoP.
Statistical analysis
Group equivalence for participant age, duration of type 2
DM, duration of DM and DPN symptoms, statin use,
presence of other diabetic complications, and hemoglobin
A1C were compared by one-way ANOVA testing; gender
was compared by chi-square testing using Fisher’s exact
test to calculate two tailed p values. Chi-square testing
was also used to compare the presence of other diabetic
complications. The primary outcome measure was a mean
difference in plasma oxLDL levels. To test for statistical
differences in plasma oxLDL levels between groups, we
performed individual ANOVA testing between the follow-
ing cohorts of interest: 1) subjects with DPN (DPN-P and
DPN-NoP subjects) compared with DM only subjects; 2)
subjects with DPN-P compared with DPN-NoP subjects;
3) subjects with DPN (DPN-P and DPN-NoP subjects)
compared with idiopathic peripheral neuropathy subjects;
and 4) all subjects with DM (DM only, DPN-P, and DPN-
NoP subjects) as compared with control subjects. We then
assessed for statistical differences in secondary outcome
measures including HbA1C, total cholesterol, triglyceride,
high density lipoprotein, and low density lipoprotein levels
between the aforementioned groups. We also performed
linear regression analyses to determine relationships be-
tween oxLDL levels (independent variables) and TCSS,
UENS, total cholesterol, and low density lipoprotein levels
using pair-wise Bonferroni corrections for multiple com-
parisons. A post-hoc analysis was performed with linear
regression analysis of the number of diabetic complica-
tions present (each of neuropathy, retinopathy, nephropa-
thy, cardiovascular disease, cerebrovascular disease) as the
independent variable and oxLDL levels as the dependent
variable. Finally, in DPN subjects, post-hoc linear regres-
sion analyses were performed using severity of DPN
(TCSS and UENS) as a dependent variable and independ-
ent variables of oxLDL levels, Hemoglobin A1C, total
cholesterol, triglycerides, and LDL levels. Values were
expressed as mean ± standard deviation or mean ± stand-
ard error as specified.
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